Mallinckrodt to Buy Sucampo

Dec 27, 2017

Mallinckrodt has agreed to buy Sucampo Pharmaceuticals for about $1.2 billion in cash, adding a treatment for constipation and experimental medicines targeting rare diseases to its portfolio.

Maryland-based Sucampo sells Amitiza, a drug for chronic constipation and irritable bowel syndrome. It also has two drugs in late-stage clinical trials for rare diseases.

Earlier this year, Mallinckrodt agreed to pay $100 million to settle FTC charges that its Questcor Pharmaceuticals illegally raised the price of best-selling drug, Acthar, by 85,000 percent, and bought the rights to a cheaper competing drug to keep it out of the U.S. market. Months later, Mallinckrodt, which makes generic opioid painkiller oxycodone, agreed to pay $35 million to settle allegations that it did not report suspicious drug orders.

Sun Acquisition -- a subsidiary of Mallinckrodt -- will commence a cash tender offer to purchase all of the outstanding shares of Sucampo Pharmaceuticals' common stock for $18.00 per share. The total transaction value (including anticipated payments in respect of Sucampo's debt) is approximately $1.2 billion. 

Read the press release 

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments